Thus, based on recent findings by us and others, we propose that a therapeutic approach using dual inhibitors of Akt/mTOR signaling in combination with inhibitors of androgen receptor signaling, such as Abiraterone Acetate or Enzalutamide, may effectively block androgen signaling while simultaneously inhibiting a Akt/mTOR signaling and therefore an effective treatment course for CRPC.
We await the results of the relevant clinical trials.
Written by:
Floc'h N, Abate-Shen C. Are you the author?
Departments of Urology and Pathology and Cell Biology, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY.
Reference: Oncotarget. 2012 Dec 5(Epub ahead of print)
PubMed Abstract
PMID: 23242005
